Mid
J
JNJAI Stock Diagnostic Report
J&J granted FDA priority review for Rybrevant Faspro in head and neck cancer
The FDA has granted priority review for Johnson & Johnson's cancer treatment Rybrevant Faspro for the expansion of its indications.
View Source Article ↗AI CATALYST SCORE75 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time